Category Archives: News

Gilde Healthcare company SpliceBio secures $135 Million financing to advance SB-007 in Stargardt disease and expand pipeline

GIlde Healthcare
  • Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as Gilde Healthcare and other existing investors 
  • Proceeds will support clinical development of lead program SB-007 in Stargardt disease  
  • Funding will also advance a broader pipeline of genetic medicines targeting indications in ophthalmology, neurology, and other undisclosed therapeutic areas  

 

SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.

The funding will be used to advance the clinical development of SpliceBio’s lead gene therapy candidate, SB-007 for Stargardt disease, including the ongoing interventional Phase 1/2 ASTRA study and the observational POLARIS study. SB-007 is the first dual adeno-associated viral (AAV) gene therapy cleared by the Food and Drug Administration (FDA) to enter clinical development for Stargardt disease. SB-007 has also received regulatory clearance for clinical development from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Stargardt disease is an inherited retinal disorder caused by mutations in the ABCA4 gene that leads to progressive vision loss and blindness, with no approved treatments available. SB-007 is designed to address the underlying genetic cause of the disease by producing a functional copy of the full-length ABCA4 protein with the potential to treat all patients, regardless of their specific ABCA4 mutation. The proceeds will also be used to accelerate SpliceBio’s pipeline of AAV gene therapy programs in ophthalmology, neurology, and other undisclosed indications that utilise the company’s proprietary Protein Splicing platform.

“This financing marks a pivotal milestone for SpliceBio as we advance the clinical development of SB-007 for Stargardt disease and continue to expand our pipeline across ophthalmology, neurology and beyond,” said Miquel Vila-Perelló, Ph.D., Chief Executive Officer and Co-Founder of SpliceBio. “The support from such high-quality investors underscores the strength of our programs and our unique Protein Splicing platform and its potential to unlock gene therapies for diseases that remain untreatable today. We are building a company positioned to lead the next wave of genetic medicines.”

SpliceBio is redefining and expanding the scope of diseases that can be tackled with gene therapies by addressing a fundamental limitation of AAV vectors in their inability to deliver genes that exceed their limited packaging capacity of 4.7 kilobases. Many genetic disorders remain untreatable because the necessary gene is too large to fit into the AAV vectors. SpliceBio’s unique Protein Splicing platform leverages the use of a family of proprietary, engineered proteins called inteins, originally developed at Princeton University. The company’s technology enables the splitting of the gene into two (or more) transgenes that are then delivered using dual AAV vectors. Once inside the cell, the DNA of each transgene is transcribed into messenger RNA and translated into protein. SpliceBio’s engineered inteins are designed to then assemble the full-length protein that is needed to treat the disease.

About SpliceBio 
SpliceBio is a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes. The Company’s lead program, SB-007, targets the root cause of Stargardt disease, a genetic eye disease that causes blindness in children and adults. SpliceBio’s pipeline comprises additional gene therapy programs across therapeutic areas, including ophthalmology and neurology. SpliceBio’s platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein, Protein Splicing, and protein engineering research. For additional information, please visit www.splice.bio.

About SB-007 
SB-007 is an investigational Protein Splicing dual AAV gene therapy in development for the treatment of Stargardt disease. It is designed to restore expression of the native full-length ABCA4 protein in the retina. SB-007 has been granted Orphan Drug Designation from both the FDA in the US and the European Commission in Europe. In December 2024, SB-007 received FDA IND clearance, marking the first-ever clearance for a dual AAV gene therapy in Stargardt disease. Alongside initiation of the Phase 1/2 ASTRA study, with the announcement of the first patient dosed in March 2025, SpliceBio continues to advance POLARIS, a natural history study of the disease. Both studies are actively recruiting. For more information or to enquire about participation in the studies, please visit www.splice.bio/clinical.

About Gilde Healthcare 
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in therapeutics, medtech and digital health, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags:

Nordic Capital to partner with Minerva Imaging, to support its growth journey in the radiopharmaceutical space

Nordic Capital

The investment will be made in close partnership with the founders of Minerva, marking a joint commitment to seek to accelerate the company’s growth, international expansion and further strengthening its integrated platform and service offerings, with the ambition of building a global market-leading radiopharmaceutical platform.

Minerva Imaging (“Minerva”) is a market-leading, science-driven Contract Research Organisation (“CRO”) and Contract Development and Manufacturing Organisation (“CDMO”), specialising in the development of targeted radioligand therapies — a fast-emerging and transformative field within cancer therapeutics. The partnership will support Minerva’s growth journey and ambition to build a global market-leading radiopharmaceutical platform

With deep expertise in molecular imaging and advanced oncology and cardiovascular disease models, Minerva delivers a highly differentiated, fully integrated platform that combines scientific excellence with end-to-end service capabilities. The company partners with many of the world’s leading pharmaceutical and biotechnology companies and is widely recognised for its industry-leading expertise and best-in-class capabilities. Today, Minerva employs over 150 highly skilled professionals, including a significant number of PhD-level scientists. The company has experienced rapid growth in recent years, generating revenue of more than DKK 225 million in 2024.

The global radiopharmaceuticals market is expected to be poised for significant growth over the next decade, driven by the increasing incidence of cancer and a growing demand for precision medicines. Through its partnership with Nordic Capital, Minerva is well-positioned to scale its operations and enhance its scientific capabilities, which would enable the company to provide even greater support to its customers throughout the pre-clinical and clinical development process.

“We are incredibly proud of Minerva’s progress since its founding. Our innovative solutions are making a meaningful impact for our collaborators and customers, with the ultimate goal of helping patients. We look forward to continuing this journey together with Nordic Capital, which brings extensive expertise, a strong network, and the capital needed to support our next phase. Their support enables us to work closely with our collaborators to advance the development of novel approaches that benefit patients”, said Andreas Kjaer, Chairman and Founder, Minerva.

“Our mission is to help transform translational research and drug development for patients with an unmet need. Together with Nordic Capital, we can seek to support innovation and boost our growth via organic expansion and potential selective strategic acquisitions. Partnering with Nordic Capital for our next growth phase will enable us to strengthen and extend our integrated service offerings to our valued customers and collaborators”, said Carsten H. Nielsen, CEO and Founder, Minerva.

“Minerva is a frontrunner in its field, and we are deeply impressed by the team and what they have built over the past 15 years. Its rigorous scientific approach and well-established platform positions the company strongly to capture future growth in the radiopharmaceuticals sector. As a leading healthcare investor with deep expertise across pharma, life sciences, and pharma services – and a strong track record in supporting international expansion – we are convinced Nordic Capital is uniquely positioned to support Minerva in its next phase of growth and in broadening its research-to-clinic service offering. We are excited about the opportunity for Nordic Capital to contribute to the next phase of Minerva’s journey as a partner to the founders and management”, said Jonas Agnblad, Partner and Co-Head of Nordic Capital Evolution advisory.

As a leading healthcare investor with over three decades of experience in fostering growth and international expansion, Nordic Capital is primed to support Minerva on its future growth journey. Nordic Capital will leverage its sector and in-house operational expertise together within its expert networks to facilitate continued growth and development. With a total committed capital of EUR 3.2 billion, Nordic Capital’s Evolution platform targets investments in middle-market growth companies across Northern Europe, applying Nordic Capital’s proven sector model. Minerva marks the eleventh investment made by Nordic Capital Evolution since 2021.

It has been agreed that the terms of the transaction shall not be disclosed. Completion of the transaction is expected in Q3 2025 and is subject to customary regulatory approvals and closing conditions.

Media contacts:

Nordic Capital
Katarina Janerud
Communications Manager, Nordic Capital Advisors
+46 8 440 50 50
katarina.janerud@nordiccapital.com

Minerva Imaging
Carsten H. Nielsen
CEO, Minerva Imaging
info@minervaimaging.com

About Minerva Imaging
Minerva Imaging is an integrated CRO and CDMO specialised in targeted radionuclide therapies. The company focusses on the use of advanced models within oncology, cardiovascular diseases and in vivo molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The facility located in Denmark offers best–in–industry fully integrated radiopharmaceutical research, drug development and manufacturing services. www.minervaimaging.com

About Nordic Capital
Nordic Capital is a leading sector-specialist private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and Services & Industrial Tech. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested c. EUR 28 billion in 150 investments. Nordic Capital’s most recent funds are Nordic Capital XI with EUR 9 billion in committed capital and Nordic Capital Evolution II with EUR 2 billion in committed capital, principally provided by international institutional investors such as pension funds. Nordic Capital Advisors have local offices in Sweden, the UK, the US, Germany, Denmark, Finland, Norway, and South Korea. www.nordiccapital.com.

Categories: News

Tags:

Bridgepoint partners with NMi Group to accelerate strategic growth

Bridgepoint

Bridgepoint, one of the world’s leading quoted private asset growth investors, has announced it is partnering with NMi Group (“NMi”), a pan-European provider of independent Advisory, Testing, Inspection, Certification, and Calibration (“ATICC”) services.

The transaction sees Bridgepoint Development Capital V – a lower middle-market fund focused on supporting fast-growing businesses across Europe – become the majority shareholder in NMi, with the exit of existing partner Levine Leichtman Capital Partners (“LLCP”). NMi’s management team will reinvest alongside Bridgepoint, ushering in the next chapter of growth for the business.

Founded in 1873, NMi ensures the systems, devices, and services that shape our daily lives – such as electric vehicle (EV) charging infrastructure, smart meters, medical devices, mobile and payment technologies, industrial control systems and safety-critical instrumentation – are accurate, fully compliant and future-ready.

The company has built a leading platform designed to meet the mission-critical demands of clients bringing new and enhanced technologies to market, often in highly regulated environments – supporting clients across the UK, Europe, Asia and the Americas with market access services such as metrology, hazardous environment safety and cyber security certification. The business also provides a range of regulatory-driven in-life services to ensure products remain compliant and accurate throughout their use, including complex calibrations, verification services, and compliance assurance.

With c.300 employees across nine sites, NMi serves over 7,000 clients in high-stakes sectors such as energy and utilities, technology, manufacturing, defence, transport and life sciences. Growth in recent years has been strong, driven by a combination of organic momentum and a disciplined buy-and-build strategy – underpinned by a series of strategic acquisitions since 2020.

NMi operates in a large and expanding global market for market access and in-life services. Growth is fuelled by increasing product complexity, evolving regulations, and rising demand for high-trust, impartial assurance –particularly in cybersecurity, industrial battery energy storage systems (BESS), and connected infrastructure. Anticipated regulatory changes, such as the EU Cyber Resilience Act and ongoing investment in energy transition and smart technologies, are expected to further accelerate demand for NMi’s services.

Bridgepoint will support NMi in scaling its international platform through continued investment in high-growth certifications and adjacent capabilities. The focus will include geographic expansion into regions such as the DACH and Nordic countries, and the development of enhanced commercial infrastructure. With its proven track record of scaling technical services and certification businesses, Bridgepoint will support NMi’s ambition to become a global leader and trusted technical partner in sectors like Energy Transition, Smart Mobility, and Digital Infrastructure.

Bridgepoint has deep ATICC sector experience through investments in companies such as Element Materials Technology, LGC, and Fera Science. Its partnership with NMi builds on this legacy and reinforces Bridgepoint’s strategy of investing in knowledge-led, high-growth businesses, including prior investments in Achilles, Sinari, and Surikat.

Matt Legg, Partner at Bridgepoint, said:

“NMi is a rare and high-quality international ATICC platform with an outstanding reputation for quality and trust, underpinned by a unique heritage and highly technical team. The business offers a compelling combination of sector-leading organic growth with significant further potential for M&A as the acquirer of choice in its space. With rising regulation and complexity across end markets, NMi is well-positioned to become a global leader in market access and in-life compliance services—an ambition we look forward to supporting alongside its management team.”

Yvo Jansen, CEO of NMi Group, added:

“This partnership aligns our long-term strategy with stakeholder needs. Bridgepoint brings deep sector experience and international reach—key as we support clients navigating increasingly complex regulatory landscapes. I’d also like to thank LLCP, who helped us scale with focus and discipline. With that strong foundation, we’re ready for the next stage—with our clients and new partners.”

Joanne Spick, CFO, NMi Group, commented:

“As regulatory demands grow, our clients need more than compliance—they need confidence. That means reliable services, smarter systems, and partners who are thinking long-term. With Bridgepoint’s support, we’ll keep investing in capabilities that matter, helping clients stay ahead and scale with assurance.”

Bridgepoint was advised on the transaction by DC Advisory (M&A and debt), Houthoff and Ropes & Gray (Legal), BCG (Commercial), BDO (Financial) and EY (tax). LLCP and NMi were advised by Houlihan Lokey (lead M&A), Rothschild (M&A), Nauta Dutilh (Legal), OC&C (Commercial), PwC (Financial and Tax) and Jamieson (Management).

The transaction is expected to complete in Q3 2025, subject to customary regulatory approvals and works council advice. Financial terms of the transaction were not disclosed.

Categories: News

Tags:

Bridgepoint prices reset of Bridgepoint CLO V

Bridgepoint prices reset of Bridgepoint CLO V

Bridgepoint has today announced the successful pricing of the reset of Bridgepoint CLO V.

The transaction extends the investment period to 2030 and lowers the cost of capital of the original 2023 deal.

Bridgepoint’s third CLO transaction of 2025, the reset saw strong demand throughout the full capital stack, evidencing the market’s continued appetite for Bridgepoint’s disciplined approach to investment and credit selection.

Commenting on the transaction, John Murphy, Partner and Bridgepoint’s Head of Syndicated Debt, said:

“We’re pleased to have seen such strong continued interest from our broader investor base with the reset of Bridgepoint CLO V. By combining a long-term reinvestment horizon with a flexible, high-conviction approach to portfolio management, we’ve shown our platform can adapt to changing markets and unlock consistent value. This robust investor demand speaks to the trust placed in our differentiated approach.”

With more than €14 billion of assets under management in corporate credit across the risk/reward spectrum, Bridgepoint Credit is one of Europe’s most experienced credit managers. It focuses on three complementary investment strategies: Direct Lending, Credit Opportunities and Syndicated Debt.

Bridgepoint Group is one of the world’s leading quoted private asset growth investors, specialising in private equity, infrastructure and private credit.

With over $86 billion of assets under management and a strong local presence in Europe, North America and Asia, we combine global scale with local market insight and sector expertise, consistently delivering strong returns through cycles.

Bridgepoint Advisers Limited, a subsidiary of Bridgepoint Group plc, is authorised and regulated by the Financial Conduct Authority.

Categories: News

Tags:

WEAVE LIVING and KKR Build on Strategic Partnership with Acquisition of Portfolio of Residential Properties in Prime Central Tokyo

KKR

Over 240 new units in upscale Tokyo locations set to open from Autumn 2025

TOKYO–(BUSINESS WIRE)– WEAVE LIVING, Asia-Pacific’s pre-eminent living sector specialist, and KKR, a leading global investment firm, today announced the signing of definitive agreements to acquire six properties in prime Tokyo locations. The move builds on the continued momentum of the Weave Living Japan Residential Venture I (“WLJRV I”) strategic partnership between WEAVE LIVING and KKR. With the latest acquisitions, the strategic partnership has grown its portfolio to 17 properties within the first six months of its establishment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609398797/en/

Three of these new acquisitions are located in Tokyo’s upscale Minato ward neighbourhoods of Roppongi, Minami Azabu and Shirokane. WEAVE LIVING will also introduce its premium WEAVE RESIDENCES brand as part of its Roppongi and Minami Azabu offerings, featuring luxurious, metropolitan living in spacious, fully furnished family-friendly homes, complete with modern decor, and thoughtful design finishes. These homes will help meet growing demand by discerning executives seeking an elevated living experience in the supply-constrained Minato area.

The remaining locations will expand the WEAVE PLACE brand, offering beautifully designed private apartments with various furnished options catering to the respective needs of a diverse tenant base including local professionals, expatriates and corporates. Under these plans, more than 240 fully-furnished luxury rental properties are expected to be ready starting from fall 2025.

“As part of our steady growth in the Japan market and across Asia-Pacific, we are thrilled to expand our collaboration with KKR and our Japan-based offering to six new locations that are extremely desirable even by Tokyo standards,” said Sachin Doshi, Founder and Group CEO of WEAVE LIVING. “Also factoring in the planned Japan debut of our WEAVE RESIDENCES brand, this is a further demonstration of our commitment to offering an ever-wider selection of living options to renters at various life stages, with an emphasis on the distinctive attractiveness of each of the fantastic locations that make up our expanded portfolio in Tokyo.”

Kensuke Kudo, Managing Director, Real Estate, KKR, said, “We are proud of the strong momentum that our strategic partnership with WEAVE LIVING has achieved in a short span of time. This expansion underscores our conviction in the long-term fundamentals of Japan’s residential sector and ability to deliver high-quality, differentiated offerings to meet the evolving residential needs of corporates and executives in Japan. We look forward to continued collaboration with Sachin to scale this promising platform.”

KKR is making its investment from its Asia real estate strategy. The transaction adds to KKR’s continued activity and momentum in Japan’s real estate sector across different real estate investment strategies, including KJR Management, a leading Japanese real estate manager that oversees two J-REITs; hospitality and office assets across Japan; and a portfolio of multifamily properties in Tokyo.

A full overview of WEAVE LIVING’s existing Tokyo locations can be found on the recently revamped WEAVE LIVING website, along with details on a unique rental offering that includes flexible lease periods; transparent payment plans inclusive of all Wi-Fi and utilities; a fully digital-first leasing experience; tenant support via the proprietary WEAVE LIVING mobile app; and a welcome respite from prohibitive up-front charges typical in the Japanese multi-family rental market.

Leasing enquiries
Tel: (+81) 03-6262-5628
Email: live.jp@weave-living.com

Existing locations: Weave Place – Shinkamata, Weave Place – Kanda East, Weave Place – Asakusa South, Weave Place – Asakusa Kaminarimon, Weave Place – Ueno South, Weave Place – Waseda Park, Weave Place – Higashi-Koenji, Weave Place – Monzennakacho, Weave Place – Morishita, Weave Place – Ryogoku, Weave Place – Kunitachi

For full details of property lineup and available units, and to request viewings, please visit https://www.weave-living.com/en/jp/

About WEAVE LIVING
Weave Living is a leading provider of urban rental accommodation in key gateway cities throughout Asia Pacific. Since its founding in 2017 by Sachin Doshi, Weave has reimagined renting a home in big cities so more people can live their best life, wherever they are on their adventure. Weave currently offers four unique living options that cater to a diverse range of modern lifestyles: luxurious Weave Residences; fully serviced Weave Suites; self-contained Weave Place; and social co-living Weave Studios. Each class-leading home combines modern aesthetics, superior finishes, and a fully tech-enabled experience together with superior comfort and flexibility in the best urban locations. At present, Weave owns and manages residential properties in Hong Kong, Singapore, Japan, and South Korea, with more on the way.

Weave Living
Website: https://www.weave-living.com/en/jp
Instagram: @liveatweave
Facebook: @liveatweave

About KKR
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

Media Enquiries
This press release is disseminated by Kyodo PR on behalf of Weave Living. For more information or for interview opportunities, please contact:

David McMahon (English)
Email: davidhoward.mcmahon@kyodo-pr.co.jp
Tel: (+81) 080-8914-9376

Aya Asoshina (Japanese)
Email: a-asoshina@kyodo-pr.co.jp
Tel: (+81) 070-4303-7299

For KKR:
Wei Jun Ong
+65 6922 5813
WeiJun.Ong@kkr.com

Source: KKR

 

Download PDF

Categories: News

Tags:

HarbourView Closes on $500 Million in Additional Debt Financing from KKR

KKR

NEWARK, N.J., June 9, 2025 /PRNewswire/ — HarbourView Equity Partners (HarbourView), an alternative asset management company focused on investment opportunities in the entertainment, media, and sports space, with approximately *$2.67B in regulatory assets under management, has closed an additional $500 million in debt financing through a new private securitization backed by its diversified, scaled music portfolio. Insurance vehicles managed by KKR, a leading global investment firm, participated in the transaction.

This latest financing expands on the nearly $500 million in debt financing HarbourView secured in 2024 from KKR-managed insurance vehicles and accounts and other investors.

“We are thrilled to have KKR’s continued support as we further scale the firm,” said HarbourView Founder and CEO Sherrese Clarke. “This additional capital from KKR will help us accelerate our strategy to align with where the media, sports and entertainment markets are headed. We see a tremendous opportunity to continue investing in evergreen intellectual property, which we believe is historically uncorrelated to broader market volatility and forms a powerful diversification tool.”

“We are pleased to further support HarbourView and to invest in this well-diversified, scaled and high-quality portfolio through our High-Grade Asset-Based Finance strategy. Music IP is one of many areas of opportunity that we see for this strategy and an example of its breadth,” said Avi Korn and Chris Mellia, Global Co-Heads of Asset-Based Finance at KKR.

KKR’s Asset-Based Finance (ABF) strategy focuses on privately originated and negotiated credit investments that are backed by large and diversified pools of financial and hard assets, offering diversification to traditional corporate credit and attractive risk-adjusted returns. KKR’s ABF platform began investing in 2016 and now has approximately $74 billion in ABF assets under management globally across its High-Grade ABF and Opportunistic ABF strategies.

Established in 2021, HarbourView Equity Partners has solidified its position in the industry, building a distinctly diverse portfolio featuring thousands of titles spanning numerous genres, eras, and artists. With data analytics and value creation at its core, the firm seeks to deliver differentiated returns in partnership with the creative ecosystem. The firm has acquired over 70 music catalogs encompassing over 35,000 songs across both master recordings and publishing income streams. The company most recently made a deal to finance a slate of Hip Hop biopics in partnership with Will Smith’s Westbrook Studios, Flavor Unit and Jesse Collins Entertainment, starting with a Queen Latifah biopic. This followed an investment in Usher’s 2024 concert film “Rendezvous in Paris.”

The financing, solely structured by Barclays, further emphasizes HarbourView’s commitment to targeting the best execution for its growing LP base and comes on the heels of numerous major deals.

“Barclays is proud to once again support HarbourView. This deal underscores the strong demand from investors for uncorrelated assets and highlights our track record of supporting music and media companies in accessing efficient, scalable capital,” said Salina Sabri, Managing Director, Securitized Products Origination at Barclays. “We are grateful to play a small role in HarbourView’s continued growth”.

Barclays served as sole structuring advisor in this transaction. Barclays and KKR Capital Markets acted as placement agents, and Fifth Third Bank, National Association as passive placement agent.

About HarbourView Equity Partners

HarbourView Equity Partners is an investment firm focused on opportunities to support premium content across the entertainment, sports, and media markets. The firm seeks businesses or assets powered by IP and investment opportunities that aim to build enduring asset value and returns. HarbourView has been extremely active since launching in 2021, amassing roughly $2.67 billion* in regulatory assets under management including over 70+ music catalogs to date and investments in various portfolio companies with management teams in its core industries. The firm’s distinctly diverse music portfolio features thousands of titles spanning numerous genres, eras, and artists, amounting to a diversified catalog of ~35,000+ songs across both master recordings and publishing income streams. The company is headquartered in Newark, NJ.

Home Page ● LinkedIn ● Instagram ● Facebook

* Unaudited as of 12/31/2024

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Barclays

Our vision is to be the UK-centred leader in global finance. We are a diversified bank with comprehensive UK consumer, corporate and wealth and private banking franchises, a leading global investment bank and a strong, specialist US consumer bank. Through these five divisions, we are working together for a better financial future for our customers, clients and communities. The Investment Bank helps money managers, financial institutions, governments, supranational organisations and corporate clients manage their funding, investing, financing, and strategic and risk management needs. www.barclays.com/ib.

*Regulatory AUM for private funds are calculated regardless of the nature of the gross assets under management. This includes any uncalled committed capital pursuant to an obligation to make a capital contribution to the fund.

SOURCE HarbourView Equity Partners

 

Download PDF

Categories: News

Tags:

EQT Life Sciences Leads USD 80 Million Series A Funding Round in Mosanna Therapeutics to Advance Sleep Apnea Nasal Spray

Life Sciences

  • Series A Funding will be used to advance Mosanna’s nasal spray therapy through Phase 2 Clinical Trials
  • Biotech veteran David Weber has been appointed CEO to lead the company through clinical development
  • Obstructive sleep apnea (OSA) affects nearly 1 billion people globally, with the majority undiagnosed and underserved with current treatment options

EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Mosanna Therapeutics (“the Company”). The clinical-stage biotech company headquartered in Basel, Switzerland, is developing an easy-to-use nighttime nasal spray to treat obstructive sleep apnea (OSA) that aims to restore the body’s natural airway control. The financing was led by EQT Life Sciences and Pivotal bioVenture Partners, along with Forbion, Broadview Ventures and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures as well as Supermoon Capital and High-Tech Gründerfonds (HTGF).

“What sets Mosanna apart is its fundamentally different approach to sleep apnea, treating it as a neurological and muscular dysfunction rather than a purely mechanical issue” said Daniela Begolo, Ph.D., Managing Director at EQT Life Sciences, who will be joining the Board of Directors. “MOS118 is the first therapy with the potential to restore the body’s natural airway reflex with the simplicity of a nasal spray. MOS118 has the potential to dramatically improve adherence and outcomes in a patient population that has long been underserved.” 

OSA is the most common sleep-related breathing disorder, affecting an estimated 1 billion people globally. Left untreated, OSA is linked to serious health risks including hypertension, cardiovascular disease, stroke, depression and excessive daytime sleepiness – contributing to workplace and car accidents. Despite OSA’s prevalence, treatment has largely focused on mechanical solutions that are often uncomfortable and disruptive. 

Mosanna is pioneering a pharmaceutical solution for sleep apnea patients with MOS118, a nasal spray administered at nighttime that helps restore the body’s natural airway reflex. MOS118 targets the upper airway muscles that are responsible for maintaining airway patency. Research has shown that in OSA patients, the natural airway reflex becomes less active at night, leading to a loss of airway patency and the occurrence of apnea. The new funding will support the advancement of MOS118 through Phase 2 development while also supporting the expansion of Mosanna’s pipeline. 

Mosanna also appointed veteran biotech leader David Weber, Ph.D., as President and Chief Executive Officer to guide Mosanna’s next stage of growth. With more than 30 years of experience spanning drug development, capital formation and corporate strategy, Dr. Weber has led teams across both public and private life sciences companies. Dr. Weber was also appointed to Mosanna’s Board of Directors. 

“Mosanna is taking a truly transformational approach to sleep apnea treatment – offering a non-invasive, non-mechanical solution designed to seamlessly fit into daily life,” said Dr. Weber. “No one has sleep apnea while awake, because our bodies instinctively keep the airway open. Mosanna simply helps to restore this natural reflex during sleep – delivering a nasal spray alternative to invasive mechanical workarounds. With this funding, we’re accelerating development to bring this groundbreaking treatment to patients who desperately need better options.” 

Contact
EQT Press Office, press@eqtpartners.com

Downloads

About EQT Life Sciences

EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients.

 

About Mosanna Therapeutics 

Mosanna Therapeutics is a clinical-stage biotech company pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) with an easily administered nasal spray. Designed to help restore the body’s natural airway control during sleep, Mosanna’s lead therapy, MOS118, offers a drug-based alternative to traditional mechanical treatments and is currently being evaluated in a Phase 1 clinical trial. Founded in 2022, the company has raised over $80 million from investors including EQT Life Sciences, Pivotal bioVenture Partners, Forbion, Norwest, Broadview Ventures, Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds (HTGF). Mosanna has offices in Redwood City, California and Basel, Switzerland. For more information, visit mosanna.com

Categories: News

Tags:

BCI Invests in KKR Tower Platform Pinnacle Towers

KKR

SINGAPORE & VICTORIA, Canada–(BUSINESS WIRE)– KKR, a leading global investment firm, British Columbia Investment Management Corporation (“BCI”), and Pinnacle Towers, an Asia-based digital infrastructure platform with a focus on the Philippines, today announced the signing of definitive agreements under which BCI will acquire a minority stake in Pinnacle Towers from KKR, which will remain the majority shareholder.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608594472/en/

Pinnacle Towers was established in 2020 to serve the rapidly increasing demand for connectivity and quality telecommunications infrastructure in the Philippines. Led by a highly experienced management team, the platform specializes in executing on Build-to-Suit (“BTS”) telecommunications tower projects, optimizing the use and management of Sale-and-Leaseback (“SLB”) assets with leading mobile network operators, and providing ancillary management services to industry players. In the span of five years, Pinnacle Towers has scaled to become the largest independent tower company in the Philippines with around 7,000 towers.1

Lincoln Webb, Executive Vice President & Global Head, Infrastructure & Renewable Resources, BCI, said, “We are excited to work closely with KKR and Pinnacle’s management team to support the growth of the business. The Philippines represents a compelling market for long-term capital, especially in essential digital infrastructure services. This investment aligns with our emerging markets strategy of backing high-quality infrastructure assets alongside strong institutional partners. We look forward to supporting Pinnacle Towers as it continues to enhance digital connectivity and drive meaningful impact across the Philippines.”

Projesh Banerjea, Managing Director, Infrastructure, KKR, said, “We are very proud of the success that we have achieved with Pinnacle Towers to serve the Philippines’ connectivity needs. Since our initial investment, we have collaborated closely with Pinnacle Towers’ outstanding management team to deepen the platform’s capabilities and scale its presence organically and through bolt-on acquisitions. We are delighted to welcome BCI, who share our long-term vision and commitment to developing critical digital infrastructure, as strategic partners and look forward to building on Pinnacle Towers’ strong growth momentum.”

Patrick Tangney, Chairman and CEO of Pinnacle Towers, said, “Over the last five years, with the support of KKR, Pinnacle Towers has grown to become the leading independent tower company in the Philippines. BCI’s investment marks an important milestone in our journey and is a strong endorsement of our mission. With BCI and KKR as strategic partners, we are well-positioned to continue driving greater digital connectivity in the Philippines and across the region.”

BCI Infrastructure & Renewable Resources has a global portfolio with nine active investments in the Asia-Pacific region, including Rakuten Mobile (a leading communications tower company in Japan), Altius (a leading communications tower company in India), and Cube Highways (the largest toll road operator in India). The program continues to expand its presence in the region with the addition of this minority stake acquisition in Pinnacle Towers.

KKR made its investment in Pinnacle Towers from its Asia Infrastructure Funds I and II. KKR first established its global infrastructure team and strategy in 2008 and has since been one of the most active infrastructure investors around the world. KKR’s Asia Pacific infrastructure platform was established in 2019 and has since organically grown to approximately US$13 billion in assets under management.

The transaction is expected to be completed by Q3 2025, subject to customary regulatory approvals.

About BCI

British Columbia Investment Management Corporation (BCI) is amongst the largest institutional investors in Canada, with C$250.4 billion in gross assets under management as of March 31, 2024. Based in Victoria, British Columbia, with offices in Vancouver, New York, and London, U.K., BCI manages a portfolio of diversified public and private market investments on behalf of its British Columbia pension fund and institutional clients. Learn more at www.bci.ca.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Pinnacle Towers

Pinnacle invests in, builds and operates telecommunications infrastructure with a focus on towers and related assets. Pinnacle is an Asia-focused digital infrastructure platform with a strong focus on the rapidly growing Philippines market. Frontier’s leadership team includes founders of a number of highly successful tower companies and former C-level executives from some of the world’s leading wireless operators. KKR first invested in Pinnacle Towers in 2020.

_____________________

1 Including sites contracted to build or acquire

 

Media Contacts

For BCI
Olga Petrycki
+1 778 410 7310
media@bci.ca

For KKR Asia Pacific
Wei Jun Ong
+65 6922 5813
WeiJun.Ong@kkr.com

For Pinnacle Towers
Hendrik-Jan Kroon
Hendrik@frontiertowersphilippines.com

Source: KKR

 

Download PDF

Categories: News

Tags:

NextGen Healthcare Welcomes Madison Dearborn Partners as New Investment Partner and Announces Planned Leadership Succession

No Comments
Thomabravo

MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo and Company Management to Accelerate NextGen Healthcare’s Growth

NextGen Healthcare President and COO Srinivas (Sri) Velamoor will Succeed David Sides as CEO after Planned Transition Period; Sides will Continue to Serve on Board of Directors and Remain Material Investor

CHICAGO & SAN FRANCISCO & REMOTE-FIRST COMPANY—NextGen Healthcare, Inc. (“NextGen Healthcare” or the “Company”), a leading provider of innovative, cloud-based healthcare technology solutions, today announced that funds affiliated with Madison Dearborn Partners, LLC (“MDP”), a leading private equity investment firm based in Chicago, have completed their acquisition of a significant ownership position in NextGen Healthcare. Thoma Bravo, a leading software investment firm, retains a significant ownership position in NextGen Healthcare. MDP will partner with Thoma Bravo and Company management to accelerate NextGen Healthcare’s growth.

Since acquiring NextGen Healthcare in a take-private transaction in 2023, Thoma Bravo has helped the Company modernize and enhance its capabilities, solutions, and operating structure to enhance the client experience. As partners, MDP and Thoma Bravo plan to jointly underwrite a material increase in annual R&D investment over the next three years and work with NextGen Healthcare’s leadership team to accelerate the delivery of best-in-class solutions and services to more healthcare clients.

NextGen Healthcare also announced that its Board of Directors has appointed NextGen Healthcare’s President and Chief Operating Officer Srinivas (Sri) Velamoor, as Chief Executive Officer, effective following a planned transition period. Velamoor will succeed David Sides, who will continue to serve on the Board and remain a material investor in NextGen Healthcare. Sides will work closely with Velamoor to ensure a seamless transition and will continue to support the Company’s strategic priorities throughout the transition period and beyond. Velamoor has been instrumental in driving NextGen Healthcare’s growth and innovation agenda in his current role and will assume full responsibility for leading the Company through its continued expansion and development, which is underpinned by the increased investment and ongoing support from MDP and Thoma Bravo.

The choice to elevate an established industry leader and company insider through a thoughtful and seamless transition process reflects the continued commitment of the NextGen Healthcare Board and leadership team to sustaining the Company’s growth and performance momentum and delivering market-leading services to clients.

“It has been an honor to work alongside Sri in leading NextGen Healthcare through its transformation the last several years. I am grateful to our entire NextGen Healthcare team and to our clients for their trust and partnership,” said Sides. “I am excited to support Sri as he takes the reins and leads us into this next phase of accelerating growth and impact for our clients in partnership with MDP and Thoma Bravo.”

“Our investment strategy centers around partnership with management. When we invested in NextGen Healthcare it was apparent to us how integral Sri has been to all aspects of the Company’s success. The succession announcement today is a natural progression from his previous leadership roles with the Company,” said Peter Hernandez, a Senior Vice President at Thoma Bravo. “We are excited for this next chapter with Sri at the helm, and we are pleased that David will continue to play an important role in the success of NextGen Healthcare as a member of the Board.”

“David’s vision and leadership have been instrumental in further cementing NextGen Healthcare as a category leader in the ambulatory Electronic Health Record space,” said Jason Shideler, Partner and Co-Head of Healthcare at MDP. “We are excited to partner with him and Sri to implement a succession plan for the Company and its clients as NextGen Healthcare continuously builds momentum and delivers market leading solutions and a world class service experience.”

“We are excited to welcome the MDP team as strategic partners and look forward to continuing to work with Sri and David in their new roles as they effect a seamless transition and lead this storied healthcare technology franchise into the next chapter of its growth and innovation journey,” said A.J. Rohde, Senior Partner at Thoma Bravo.

“I am humbled and privileged to be entrusted with the leadership of NextGen Healthcare’s incredible global team and to lead us through our next phase of growth and innovation,” said Velamoor. “Our colleagues, clients, and partners are unified behind our vision of achieving Better Healthcare Outcomes for All. And we are incredibly excited to partner with Thoma Bravo and MDP to unlock the many opportunities in front of us to elevate practice performance and reimagine the provider and patient experience.”

Advisors
Goodwin Procter LLP served as legal counsel to NextGen Healthcare. Morgan Stanley & Co. LLC served as lead financial advisor and J.P. Morgan Securities LLC and Evercore also served as financial advisors to NextGen Healthcare. Kirkland & Ellis, LLP served as legal counsel to MDP.

About NextGen Healthcare, Inc.
NextGen Healthcare, Inc. is a leading provider of innovative healthcare technology and data solutions. We are reimagining ambulatory healthcare with award-winning Electronic Health Record (EHR), practice management and surround solutions that enable providers to deliver whole-person health and value-based care. Our highly integrated, intelligent, and interoperable solutions increase clinical quality and productivity, enrich the patient experience and drive superior financial performance. We are on a relentless quest to achieve better healthcare outcomes for all. Learn more at nextgen.com, and follow us on Facebook, X, LinkedIn, YouTube, and Instagram.

About Madison Dearborn Partners
Madison Dearborn Partners, LLC (“MDP”) is a leading private equity investment firm based in Chicago. Since MDP’s formation in 1992, the firm has raised aggregate capital of more than $31 billion and has completed over 160 platform investments. MDP invests across four dedicated industry verticals, including healthcare, basic industries, financial services, and technology & government. Drawing on deep industry and operational expertise, MDP works closely with management teams to drive value creation and operational improvement across its portfolio. For more information, please visit www.mdcp.com

About Thoma Bravo
Thoma Bravo is one of the largest software-focused investors in the world with a 40+ year history and approximately $184 billion in assets under management as of March 31, 2025. Through our private equity, growth equity and credit strategies, our firm invests in growth-oriented, innovative companies operating in the software and technology sectors. Our firm has acquired or invested in approximately 535 software and technology companies representing approximately $275 billion of value (including control and non-control investments). Our investment philosophy is centered around working collaboratively with existing management teams to help drive operating results and innovation. Leveraging our deep sector knowledge and strategic and operational expertise, we execute through a partnership-driven approach supported by a set of management principles, operating metrics and business processes. We support our companies by investing in growth initiatives and strategic acquisitions designed to drive long-term value.

Read the release on Business Wire here.

Categories: News

Tags: